Impact of hypoglycemic drugs on the course of COVID-19 in patients with type 2 diabetes mellitus

Yasmin Ahmed Ali El-Taravi , Emiliya S. Rassadina , Valeriya S. Kuzenkova , Tatiana S. Kokorina , Alina I. Dzarasova , Ella T. Rogava , Irina A. Kuzina , Narine S. Martirosyan , Nina A. Petunina

For citation:

Abstract

Diabetes mellitus and hyperglycemia are independent risk factors for morbidity, severe course, and adverse outcomes of a nevel coronavirus infection. The article discusses the features of the course of COVID-19 in patients with diabetes. Chronic hyperglycemia is associated with endothelial dysfunction, increased expression of pro-inflammatory cytokines, and a hypercoagulable state that aggravates the course of a viral infection. In turn, COVID-19 is associated with an increased risk of manifestation of diabetes mellitus, the SARS-CoV-2 virus can act as a potential trigger agent. There are still a number of unresolved questions, in particular, whether the virus can cause the manifestation of a special type of diabetes. No less relevant is the issue of optimal hypoglycemic therapy in patients with type 2 diabetes and COVID-19. Hypoglycemic therapy, by influencing various links in the pathogenesis of diabetes mellitus and lowering the level of glycemia, can potentially reduce the risks of complications and severe course of COVID-19 in patients with diabetes mellitus.

Key words: diabetes mellitus, COVID-19, hypoglycemic therapy.

References

1. Wu Z-H, Tang Y, Cheng Q et al. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetologica 2021; 2 (58): 139–44.

2. Holman N, Knighton P, Kar P et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabet Endocrinol 2020; 10 (8): 823–33.

3. Sarkar S, Das D, Borsingh Wann S et al. Is diabetes mellitus a wrongdoer to COVID-19 severity? Diabetes Res Clin Pact 2021; 178: 108936.

4. Zhou L, Niu Z, Jiang X et al. SARS-CoV-2 Targets by the pscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases. iScience 2020; 11 (23): 101744.

5. Lim S, Bae JH, Kwon HS et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews. Endocrinology 2021; 1 (17): 11–30.

6. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020; 10223 (395): 497–506.

7. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011; 12 (32): 734– 39.

8. Bojkova D, Klann K, Koch B et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 2020; 583: 469–72.

9. Codo AC, Davanzo GG, Monteiro LB et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF1α/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437–46.e5.

10. Zhu L, She ZG, Cheng X et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 31: 1068–77.e3.

11. Kahleova H, Tura A, Klementova M et al. A Plant-Based Meal Stimulates Incretin and Insulin Secretion More Than an Energy – and Macronutrient-Matched Standard Meal in Type 2 Diabetes: A Randomized Crossover Study. Nutrients 2019; 11: 486.

12. Raj VS, Mou H, Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251–4.

13. Kleine-Weber H, Schroeder S, Krüger N et al. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 2020; 9: 155–68.

14. Meyerholz DK, Lambertz AM, McCray PB et al. Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract. Am J Pathol 2016; 186: 78–86.

15. Mirani M, Favacchio G, Carrone F et al. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care 2020; 43 (12): 3042–9. DOI: 10.2337/dc20-1340

16. Solerte SB, D'Addio F, Trevisan R et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, CaseControl, Retrospective, Observational Study. Diabetes Care 2020; 43: 2999–3006.

17. Nafakhi H, Alareedh M, Al-Buthabhak K et al. Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes Metab Syndr 2021; 15: 33–8.

18. Dalan R, Ang LW, Tan WYT et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother 2021; 7: e48–e51.

19. Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord 2021; 20: 543–50.

20. Kan C, Zhang Y, Han F et al. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and MetaAnalysis. Front Endocrinol 2021; 12: 708494.

21. Shah F, Mahmud H, Gallego-Martin T et al. Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis. J Clin Endocrinol Metab 2019; 104: 5274–84.

22. Bloodworth MH, Rusznak M, Pfister CC et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology. J Allergy Clin Immunol 2018; 142: 683–7.

23. Mustafa OG, Whyte MB. The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential. Diabetes Metab Res Rev 2019; 35.

24. Shestakova MV, Mokrysheva NG, Dedov II. Course and treatment of diabetes mellitus in the context of COVID-19. Diabetes Mellit 2020; 23: 132–9.

25. Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46: 423–6.

26. Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol 2021; 93: 695–697.

27. Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Res Clin Pract 2020; 164: 108183.

28. Niu M-J, Yang J-K, Lin S-S et al. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 2008; 34, 56–61.

29. Kim J, You YJ. Regulation of organelle function by metformin: regulation of organelle function by metformin. IUBMB Life 2017; 69: 459–69.

30. Cheng X et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 32: 537–47.

31. Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75: 422–34.

32. Daniele G et al. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 2016; 39: 2036–41.

33. Kahkoska AR et al. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Diabetes Care 2021; 44: 1564–72.

34. Kosiborod MN et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021; 9: 586–94.

35. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract 2020; 163: 108146.

36. Patoulias D, Papadopoulos C, Boulmpou A, Doumas M. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes Metab 2021. DOI: 10.1111/dom.14359

37. Hossain U, Das AK, Ghosh S, Sil PC. An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. Food Chem Toxicol 2020; 145: 111738.

38. Zhang N et al. Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China. Front Endocrinol 2020; 11: 571037.

39. Yan H et al. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. Clin Pharmacol Ther 2020; 108: 1185–94.

40. Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ Can MedAssoc J JAssoc Medicale Can 2005; 172: 213–26.

41. Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax 2011; 66: 383–8.

42. Zhang W-Y, Schwartz EA, Permana PA, Reaven PD. Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 2008; 28: 2312–8.

For citation:El-Taravi Ya.A., Rassadina E.S., Kuzenkova N.S. et al. Impact of hypoglycemic drugs on the course of COVID-19 in patients with type 2 diabetes mellitus. Clinical review for general practice. 2023; 4 (4): 27–36. DOI: 10.47407/kr2023.4.4.00253

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice